Unexpected autocrine role of vascular endothelial growth factor in squamous cell carcinoma.
Mirones et al. demonstrate that keratinocytes deficient in VEGF are capable of forming tumors but use a distinct form of aneuploidy and signaling to form tumors. This knowledge is important because inhibitors of VEGF, including bevacizumab (anti-VEGF antibodies) and sorafenib (Braf/VEGFR2 kinase inhibitor), have already entered the clinic. These agents may "remodel" tumor signaling.
Arbiser
Jack L
JL
Department of Dermatology, Emory University School of Medicine, Atlanta, Georgia 30322, USA. jarbise@emory.edu
D000782:Aneuploidy; D000818:Animals; D000911:Antibodies, Monoclonal / Q000494:pharmacology; D061067:Antibodies, Monoclonal, Humanized; D001557:Benzenesulfonates / Q000494:pharmacology; D000068258:Bevacizumab; D002294:Carcinoma, Squamous Cell / Q000378:metabolism*; D015972:Gene Expression Regulation, Neoplastic; D051379:Mice; D008822:Mice, Transgenic; D008954:Models, Biological; D009154:Mutation; D009536:Niacinamide / Q000031:analogs & derivatives; D010641:Phenotype; D010671:Phenylurea Compounds; D011725:Pyridines / Q000494:pharmacology; D015398:Signal Transduction; D012878:Skin Neoplasms / Q000378:metabolism*; D000077157:Sorafenib; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors / Q000378:metabolism / Q000502:physiology*
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D001557:Benzenesulfonates; D010671:Phenylurea Compounds; D011725:Pyridines; D042461:Vascular Endothelial Growth Factor A; D009536:Niacinamide; D000068258:Bevacizumab; D000077157:Sorafenib